Pathway Capital Management, LP Jounce Therapeutics, Inc. Transaction History

Pathway Capital Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$7.11 - $9.64 $602,664 - $817,115	-84,763 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.04 - $8.73 $123,399 - $213,745	24,484 Added 40.62%	84,763 $630,000
Q2 2021 Aug 13, 2021	BUY	$6.58 - $10.66 $396,635 - $642,574	60,279 New	60,279 $410,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Pathway Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Pathway Capital Management, LP with notifications on news.